Investment Rating - The report maintains an "Outperform" rating for the company [6]. Core Views - The company achieved total revenue of 42.9 billion yuan in Q3 2024, representing a year-on-year increase of 24% and a quarter-on-quarter increase of 35% [6][7]. - The net profit for Q3 2024 was 2.8 billion yuan, showing a slight year-on-year increase of 0.3% and a significant quarter-on-quarter increase of 156% [6][7]. - The company expects Q4 2024 vehicle deliveries to be between 160,000 and 170,000 units, which corresponds to a year-on-year growth of 21.4% to 29.0% [6]. Summary by Sections Financial Performance - In Q3 2024, the company delivered 153,000 new vehicles, a year-on-year increase of 45% and a quarter-on-quarter increase of 41% [7]. - The average revenue per vehicle in Q3 2024 was approximately 270,000 yuan, which is a decrease of 49,000 yuan year-on-year and 9,000 yuan quarter-on-quarter [7]. - The gross margin for Q3 2024 was 21.5%, a year-on-year decrease of 0.5 percentage points but an increase of 2.0 percentage points quarter-on-quarter [8]. Profitability Metrics - The net profit margin for Q3 2024 was 6.6%, reflecting a year-on-year decrease of 1.5 percentage points but a quarter-on-quarter increase of 3.1 percentage points [8]. - The selling, general and administrative (SG&A) expense ratio was 7.8%, while the R&D expense ratio was 6.0% for Q3 2024 [8]. Sales and Revenue Forecast - The company forecasts sales of new vehicles to be 510,000, 710,000, and 850,000 units for the years 2024, 2025, and 2026, respectively [5]. - Revenue projections for the same years are 146 billion yuan, 206.4 billion yuan, and 250.2 billion yuan, respectively [5]. Valuation - The report uses the Price-to-Sales (PS) method for valuation, estimating PS ratios of 1.3, 0.9, and 0.7 for the years 2024, 2025, and 2026, respectively [5]. - The reasonable value range for the company's stock is estimated to be between 105.56 and 113.10 HKD based on a PS ratio of 1.4 to 1.5 for 2024 [5].

Investment Rating - The report maintains a "Buy" rating for Huarun Building Materials Technology (1313 HK) [7] Core Views - The report expects price elasticity in the South China market in Q4 2024, driven by seasonal factors and regional supply-demand dynamics [3][4] - The Greater Bay Area construction provides medium-term growth momentum for the South China cement market [5] - The company's strategic shift from market share to collaboration has had an immediate positive impact on regional prices [5] - The company's aggressive expansion into aggregates is entering a harvest period, providing a new growth curve [5] Financial Performance - In the first three quarters of 2024, the company reported revenue of 16 billion yuan, down 6% YoY, and net profit of 310 million yuan, down 52% YoY [3] - Q3 2024 net profit was 140 million yuan, up 77% YoY [3] - Cement and clinker sales volume was 43 86 million tons, down 7% YoY [4] - Ready-mixed concrete sales volume was 8 29 million cubic meters, up 33% YoY [4] - Aggregates sales volume was 46 28 million tons, up 71% YoY [4] Market Dynamics - National cement production in the first three quarters of 2024 was 1 327 billion tons, down 10 7% YoY [3] - New housing construction starts in the first three quarters of 2024 decreased by 22 2% YoY [3] - Infrastructure investment (excluding power, heat, gas, and water supply) grew by 4 1% in the first three quarters of 2024, lower than the 5 9% growth in 2023 [3] - Cement prices in the Yangtze River Delta region have increased by approximately 100 yuan/ton since October 2024 [4] Company Strategy - The company shifted its pricing strategy from market share to collaboration in Q2 2024, leading to significant price elasticity [5] - The company is well-positioned as a regional leader with scale and location advantages [5] - The company's aggregates business is becoming a significant contributor to growth [5] Industry Outlook - Fiscal policy adjustments and increased liquidity injection by the central bank in October 2024 are expected to benefit the cement sector [5] - Debt resolution efforts may reduce interest expenses and open up mid-term leverage space, potentially improving infrastructure demand [5] - Industry supply-side changes, including overcapacity management and carbon trading, may lead to cost increases for small enterprises and strengthen collaboration [5] Valuation - The report forecasts net profits of 660 million yuan and 1 16 billion yuan for 2024 and 2025, respectively, with corresponding P/E ratios of 19x and 11x [5]

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The core education business continues to show growth, with a revenue increase of 33.5% year-on-year to $1.278 billion, aligning with the company's previous performance guidance [1]. - The company expects net revenue for FY25Q2 to be between $850 million and $870 million, representing a year-on-year growth of 25% to 28% [1]. - The company has a strong cash reserve totaling $4.9 billion, indicating sufficient liquidity for future operations [1]. Financial Performance Summary - For FY25Q1, net income reached $2.65 billion, a year-on-year increase of 39.8% [1]. - The number of schools and learning centers increased to 1,089, with a net addition of 64 centers [1]. - The paid user base grew by 78.5% year-on-year to 3.23 million [1]. Revenue and Profitability - The company's gross margin for FY25Q1 was 53.3%, a 6.9 percentage point increase year-on-year [1]. - Non-GAAP operating profit margin was reported at 24.4%, a decrease of 2.2 percentage points year-on-year [1]. - The company anticipates a revenue growth of approximately 30% for the full fiscal year [1]. Market Position and Future Outlook - The company is expected to maintain a robust growth trajectory in its core education business, with a projected expansion of teaching points by 20% year-on-year [1]. - The target price for the company's stock is set at $89.0, reflecting a positive outlook despite potential fluctuations in profit margins [1]. - The company is focusing on expanding its national teaching network and enhancing its educational services [1].

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Insights - The company is transitioning into a manufacturer of new energy commercial vehicles, aiming to penetrate the European new energy commercial vehicle market [10] - The acquisition of 100% equity in Handerson Automotive Technology for HKD 166 million is a significant step in expanding the company's automotive business from sales and after-sales services to full-scale OEM manufacturing [2][10] - The company leverages a light-asset model to enhance efficiency and reduce costs, allowing for quicker development cycles and lower initial investments [4][5] Company Background - The company primarily engages in investment holding, with its main businesses being automotive distribution and property investment [1] - In 2023, the company reported total revenue of HKD 47.504 million, with automotive business contributing HKD 15.839 million (33%) and property investment generating HKD 31.665 million (67%) [1] Business Model and Operations - Handerson utilizes China's automotive production capacity and supply chain advantages, focusing on the development and manufacturing of new energy logistics vehicles [3] - The company has established strategic partnerships with Dongfeng Motor and JAC Motors to enhance its R&D capabilities [3] - The light-asset model allows the company to significantly reduce development time and upfront investment, exemplified by the eBOLD logistics vehicle, which took only one year from project initiation to delivery [4] Market Opportunity - The European market for new energy commercial vehicles is still in its early stages, with only 7% of new registered vans being electric as of 2023 [6][9] - The report highlights a growing demand for new energy vehicles in Europe, driven by regulatory changes aimed at reducing carbon emissions [6][9] - The company has received orders for 800 vehicles in 2024 and plans to increase this to 2,000 vehicles per month in 2025 [5] Competitive Landscape - The report notes that the penetration rate of new energy commercial vehicles in Europe is low compared to traditional diesel vehicles, presenting a significant growth opportunity [7][9] - The company faces challenges from established European manufacturers and must invest in technology and brand recognition to capture a larger market share [10]

Investment Rating - The investment rating for the company is "Buy" with a target price of 6.92 HKD, maintained from previous assessments [2]. Core Insights - The company reported a revenue of 26.35 billion HKD for the first three quarters of 2024, a decrease of 6.37% year-on-year, with a net profit attributable to shareholders of 5.668 billion HKD, down 11.38% year-on-year [2]. - The company has completed the transfer of equity in Jiangyin Sulong Thermal Power Co., resulting in a reduction of controlled installed capacity by 1.24 GW, while new units have been put into operation, leading to a total controlled installed capacity of 37.01 GW as of the end of September [2]. - The company plans to inject 4 GW of new energy assets, with an initial batch of approximately 2 GW, as part of a strategy to enhance its operational capacity and market position [2]. Summary by Sections Financial Performance - For the first three quarters, the company achieved a revenue of 26.35 billion HKD, with the wind power segment generating 19.116 billion HKD (down 8.35%), thermal power at 5.439 billion HKD (down 12.48%), and solar power at 1.568 billion HKD (up 65.51%) [2]. - The net profit for Q3 alone was 1.647 billion HKD, reflecting a year-on-year increase of 29.89%, attributed to new unit contributions and equity disposal gains [2]. Operational Highlights - The company’s wind power utilization hours decreased by 108 hours year-on-year to 1,607 hours, with wind power generation at 43.9 billion kWh, a slight decline of 1.82% [2]. - Solar and other renewable energy generation saw a significant increase of 82.76%, reaching 5.8 billion kWh [2]. Future Outlook - The company forecasts net profits attributable to shareholders of 6.6 billion, 7.5 billion, and 8.2 billion HKD for 2024, 2025, and 2026 respectively, with corresponding price-to-earnings ratios of 9, 8, and 7 times [2].

Investment Rating - The report maintains a "Buy" rating for Wynn Macau (1128 HK) [1] Core Views - Wynn Macau's Q3 2024 performance fell short of expectations, with market share remaining stable [1] - The company aims to maximize EBITDA by focusing on product and service enhancements, despite intense competition in Macau [2] - Q3 2024 adjusted property EBITDAR margin declined QoQ, though it improved compared to Q3 2019 levels [3] - Revenue recovery in Q3 2024 reached 81 2% of Q3 2019 levels, with gaming and non-gaming net revenues recovering to 78 9% and 93 8% respectively [3] - Adjusted property EBITDAR for Q3 2024 was USD 260 million, down 6 2% QoQ but recovering to 87 3% of 2019 levels [3] Financial Performance Revenue - Q3 2024 gaming revenue reached USD 880 million, recovering to 70 4% of Q3 2019 levels [1] - VIP gaming revenue recovered to 25 3% of Q3 2019 levels [1] - Mass market (including slots) gaming revenue recovered to 106 7% of Q3 2019 levels [1] - Total revenue forecast for 2024-2026: HKD 28 737 million, HKD 31 039 million, and HKD 32 661 million respectively [1] Profitability - Adjusted property EBITDA forecast for 2024-2026: HKD 8 995 million, HKD 9 587 million, and HKD 10 018 million respectively [1] - EV/Adjusted property EBITDA multiples for 2024-2026: 7 89x, 7 40x, and 7 08x respectively [1] - EPS forecast for 2024-2026: HKD 0 48, HKD 0 56, and HKD 0 64 respectively [1] Operational Metrics - Hotel occupancy rate reached 99% in July 2024 [2] - Daily operating expenses increased by 2 0% QoQ to USD 2 55 million in Q3 2024 [3] - Adjusted property EBITDAR margin was 30 2% in Q3 2024, down 1 5 percentage points QoQ but up 2 1 percentage points compared to Q3 2019 [3] Market Position - Wynn Macau's mass market recovery (106 7%) lagged behind the industry average (107 1%) in Q3 2024 [1] - VIP recovery (25 3%) was significantly below the industry average (42 1%) in Q3 2024 [1] - The company plans to optimize and expand F&B facilities and renovate Chairman's Club to enhance service quality [2] Valuation - Target price: HKD 8 2 [4] - Current price: HKD 6 00 [5] - 52-week range: HKD 4 74 - HKD 8 30 [5]

Investment Rating - The report assigns a rating of "Outperform" to the company, indicating a relative strength compared to the market performance [2][4]. Core Insights - The company's Q3 performance met expectations, with a revenue of 100.19 billion yuan for the first three quarters, representing a year-on-year increase of 22.0%. The net profit attributable to shareholders was 4.51 billion yuan, down 25.4% year-on-year [2][3]. - Q3 revenue reached 42.87 billion yuan, with a quarter-on-quarter increase of 23.6% and a year-on-year increase of 35.3%. The net profit attributable to shareholders for Q3 was 2.81 billion yuan, showing a slight decrease of 0.3% quarter-on-quarter but a significant increase of 155.2% year-on-year [2][3]. Summary by Sections Sales Performance - Q3 sales were strong, with total sales of 153,000 vehicles, a year-on-year increase of 45% and a quarter-on-quarter increase of 41%. The L6 model contributed significantly, with sales of 75,000 units, a quarter-on-quarter increase of 92%, accounting for 49.2% of total sales [3][4]. Financial Metrics - The gross margin for Q3 was 21.5%, with the automotive business gross margin at 20.9%, reflecting a quarter-on-quarter increase of 2.2 percentage points. The average selling price (ASP) per vehicle was 270,000 yuan, slightly down by 0.9 thousand yuan [3][4]. - R&D expenses for Q3 were 2.59 billion yuan, with a rate of 6.0%, down 3.5 percentage points quarter-on-quarter, indicating effective cost control [3][4]. Future Outlook - The company expects Q4 delivery volumes to be between 160,000 and 170,000 vehicles, representing a year-on-year increase of 21.4% to 29.0%. Projected revenue for Q4 is between 43.2 billion and 45.9 billion yuan, a year-on-year increase of 3.5% to 10.0% [3][4]. - The company has developed and operated 1,000 supercharging stations, leading the industry in the number of self-built high-speed charging stations, which supports the sales of high-end pure electric products [4][5]. Revenue Projections - Revenue projections for 2024 to 2026 are revised to 145.98 billion, 194.13 billion, and 215.65 billion yuan respectively. The net profit attributable to shareholders is adjusted to 7.52 billion, 12.60 billion, and 16.43 billion yuan for the same period [4][5].

Investment Rating - The report maintains a rating of "Buy" for the company [3]. Core Views - The company is demonstrating steady progress in its operations, with voluntary lock-up and share buyback reflecting confidence in future development [2]. - The company’s controlling shareholders have committed to not selling shares for six months and plan to buy back up to 100 million HKD in shares, indicating strong belief in the company's growth potential [3]. - The company is integrating its supply chain and expanding its store formats, which is expected to open new growth opportunities [3]. Financial Projections - The forecasted net profits for the company from 2024 to 2026 are 212 million, 253 million, and 312 million RMB respectively, with corresponding PE ratios of 24x, 20x, and 16x [3]. - The company’s revenue is projected to grow from 6,094 million RMB in 2023 to 6,762 million RMB in 2025, and further to 7,886 million RMB in 2026, reflecting a growth rate of 10.62% and 16.63% respectively [6]. Recent Developments - The company has recently launched a new factory in Hubei and is acquiring a 41% stake in Beihai Daixiaji Food Co., which will increase its ownership to 51% [3]. - The company is also exploring new store formats by entering agricultural markets with a new sub-brand, which is expected to enhance its market presence [3].

Investment Rating - The report maintains a "BUY" rating for the company and raises the target price to HK$20.00 from HK$15.50, implying a 21.8% upside from the current price of HK$16.42 [1]. Core Insights - The company's 3Q net profit after tax (NPAT) increased significantly by 17.7% year-on-year to RMB66.2 billion, driven by net fair value gains, which surged 80 times year-on-year [1]. - The report revises FY24-26E EPS forecasts upward by 148%, 38%, and 31% to RMB4.45, RMB2.58, and RMB2.61 respectively, reflecting improved fundamentals and investment performance [1][3]. - The company is expected to achieve a 17% growth in new business value (NBV) for FY24, supported by margin expansions and a favorable product mix [1][3]. Summary by Sections Financial Performance - The company reported a total investment income (TII) of RMB261.4 billion in 9M24, a 152% increase year-on-year, with 3Q TII soaring 5.28 times year-on-year to RMB139.1 billion [1]. - In 9M24, NBV grew by 25.1% year-on-year, indicating strong growth momentum, particularly in 3Q24, where new business sales surged [1][3]. Valuation Metrics - The stock is currently trading at FY24E 0.41x P/EV and 0.91x P/BV, which are above the respective 3-year historical averages [1][4]. - The report indicates a fair value per share of HK$20.00 based on P/EV and P/B methodologies, reflecting a robust valuation outlook [4][13]. Growth Drivers - The company is expected to benefit from a favorable equity market environment, with a significant allocation to high-dividend yield stocks anticipated to smooth out profit volatility [1][10]. - The report highlights a stable agency force with improved productivity, contributing to the positive outlook for new business sales [1][3]. Future Outlook - Management anticipates a shift in product mix towards higher sum-assured whole life and participating products for FY25, which is expected to drive sales growth [1]. - The report projects continued margin expansion and a resilient NBV growth trajectory, supported by regulatory changes and improved underwriting product mix [1][3].

Investment Rating - The report maintains a "BUY" rating for Innovent Biologics with a target price of HK$55.21, representing a 39.6% upside from the current price of HK$39.55 [3][19]. Core Insights - Innovent Biologics has demonstrated strong fundamentals supported by significant R&D catalysts and a commitment to corporate governance, as evidenced by the cancellation of a related-party transaction to protect investor interests [1][5]. - The company has shown robust product sales growth, with total product sales increasing over 40% year-on-year to more than RMB2.3 billion in Q3 2024, and a total of over RMB6.0 billion in the first nine months of 2024 [6][11]. - Innovent's product portfolio is expanding, with 11 marketed products and the anticipated approval of additional products, aiming for RMB20 billion in sales by 2027 [11][12]. Financial Performance - For FY24E, Innovent is projected to achieve revenue of RMB8.219 billion, reflecting a year-on-year growth of 32.4% [2][18]. - The company expects to narrow its non-IFRS EBITDA loss significantly, projecting a loss of RMB731 million for FY24E, with a target to achieve EBITDA breakeven by 2025 [11][19]. - R&D expenses are forecasted to be RMB2.795 billion in FY24E, indicating a continued investment in innovation [2][19]. Product Pipeline and Market Potential - Innovent's leading product, sintilimab, achieved sales of US$150 million in Q3 2024, with expectations to reach RMB3.69 billion in 2024, a 34% increase year-on-year [6][11]. - The company is advancing several innovative drug candidates, including IBI363 and IBI343, which have shown promising results in clinical trials and are expected to create significant out-licensing opportunities [13][14]. - The anticipated approval of mazdutide for obesity and diabetes in 2025 is expected to enhance Innovent's position in the cardiovascular and metabolic sector [12][15]. Market Outlook - Innovent aims to leverage its strong commercial capabilities and broad product portfolio to drive growth in both domestic and international markets [1][11]. - The company is well-positioned to capture market share in the rapidly growing sectors of oncology and metabolic diseases, with a focus on innovative therapies that address unmet medical needs [12][15].